Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older XXXX .

@entity1 @entity7856 @entity2613
UNASSIGNED: The objective of this study was to examine the association between sexual activities, problems and satisfaction, and @entity2613 and @entity7856 inhibitor (PDE5i) use. A nationally representative sample of @entity1 (n=2612) aged 51-87 years from the English Longitudinal Study of Ageing completed an in-depth Sexual Relationships and Activities Questionnaire. Associations between @entity2613 and/or PDE5i use and sexual outcomes were explored using logistic regression models adjusted for age, health and lifestyle factors. PDE5i use in the preceding 3 months was reported by a total of 191 (7%) @entity1 , whereas 542 (21%) reported @entity2613 but no PDE5i use (untreated @entity2613 ). Compared with @entity1 without @entity2613 , PDE5i users were more likely to be sexually active and report more frequent sexual intercourse. @entity1 with untreated @entity2613 reported the lowest frequency of sexual activities. Compared with @entity1 without @entity2613 , both PDE5i users and those with untreated @entity2613 were more likely to report being concerned about their level of sexual desire, frequency of sexual activities, erectile function, waking erections and orgasmic experience. PDE5i users were also more concerned about and dissatisfied with their overall sex life than @entity1 without @entity2613 . This population-based study shows that while PDE5i use is associated with improved sexual functioning, this is not equally reflected in decreased levels of concern and dissatisfaction with their overall sexual health. Clinicians should be aware of this disparity between functional gains and continuing sexual concerns and dissatisfaction, and, where appropriate, offer psychosexual counselling as an adjunct to PDE5i medication.
